A randomized, double-blind, placebo-controlled, multicentre, phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagonist therapy

Trial Profile

A randomized, double-blind, placebo-controlled, multicentre, phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagonist therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Atacicept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms AUGUST-I
  • Sponsors EMD Serono
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Mar 2011 Results published in the Arthritis and Rheumatism.
    • 19 Jun 2010 Primary endpoint results presented at the 11th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top